Vivimed Labs Ltd Overview
Identity table
| Field | Detail | Source |
|---|---|---|
| Legal name | Vivimed Labs Limited | Exchange filings 2026 |
| Former names | Emgi Pharmaceuticals & Chemicals Pvt Ltd (incorporated 22 Sep 1988); converted to public company and renamed Emgi Pharmaceuticals & Chemicals Ltd (21 Apr 1994); renamed Vivimed Labs Limited (22 Apr 1997) | Company background (Arihant Capital company profile) |
| Founding / incorporation | 22 September 1988 (some aggregators cite 1991 as founding; the statutory incorporation date is 1988) | MCA/CIN; aggregator profiles conflict |
| CIN | L02411KA1988PLC009465 | Form G (June 2026) |
| PAN | AAACV6060A | Form G (June 2026) |
| Incorporation jurisdiction | Karnataka, India (Registrar of Companies, Bangalore) | MCA records |
| Registered office | Plot No. 78-A, Kolhar Industrial Area, Bidar, Karnataka – 585403, India | Form G (June 2026) |
| Corporate office | 3rd Floor, 6-3-866/1/G1, Greenlands, Begumpet, Hyderabad, Telangana – 500016, India (per company letterhead on exchange filings) | NSE disclosure 13 Feb 2026 |
| Stock exchanges / tickers | BSE: 532660; NSE: VIVIMEDLAB (currently traded in "BE" series, trade-for-trade settlement); also referenced by Metropolitan Stock Exchange (MSE) | NSE circular 10 Dec 2025; MSE circular 17 Dec 2025 |
| ISIN | INE526G01021 | NSE circular |
| LEI | 335800LYN9TN3F87WV86 | Financialfilings.com index |
| CUSIP | Not applicable (no US listing) | — |
| Face value | INR 2 per share (historically INR 10) | NSE circular 10 Dec 2025 |
| Shares outstanding | ~82.93 million (FY2026) | S&P Global via StockAnalysis |
| Fiscal year end | 31 March | Filings |
| Employees (latest) | 552 (per Form G, June 2026); 586 cited by PitchBook | Form G; PitchBook |
| Employee trend (3-year) | Not publicly disclosed in verified form | — |
| Statutory auditor | SVRL & Co., Chartered Accountants (qualified opinions on FY2025 and FY2026) | FY2026 results coverage; FY2025 auditor report |
| Market capitalisation (current) | ~INR 54.7 crore (INR 547 million) at INR 6.59 close on 7 Oct 2026 × 82.93M shares (analyst calculation) | StockAnalysis price; share count |
| Insolvency status | CIRP admitted 15 Apr 2026, CP(IB) No. 91/BB/2025, NCLT Bengaluru; IRP T. Narayana Swamy (Reg. IBBI/IPA-002/IP-N01078/2020-2021/13427) | NCLT order; exchange filings |
| Website | https://www.vivimedlabs.com | Form G |
Vivimed Labs is a Hyderabad-managed, Bidar-registered Indian pharmaceutical manufacturer that once operated as a globally diversified specialty chemicals and API group, with subsidiaries in the UK (James Robinson), Spain and Mexico (UQUIFA), Hungary (Soneas), and the US. Over the last decade it has progressively dismantled that portfolio: selling specialty chemical product lines to Clariant (2015), exiting its US generics joint venture to Strides (2019), and ceasing to consolidate its European API arm around FY2022. What remains is a sub-scale domestic finished-dosage and API manufacturer with five plants across Telangana, Uttarakhand and Karnataka, revenue from operations of INR 699.9 million in FY2026 (down from INR 8.6 billion consolidated in FY2021), negative net worth, defaulted bank debt assigned to an asset reconstruction company, a pending CBI bank-fraud investigation (stayed by the Telangana High Court), and an active CIRP. The equity is effectively an option on a resolution outcome.
What the company does today
On the basis of its most recent statutory and insolvency disclosures, Vivimed Labs is today primarily a manufacturer of pharmaceutical dosage forms and active pharmaceutical ingredients (APIs). The IRP's Form G (14 June 2026) describes the corporate debtor as operating in the business of manufacturing pharma dosage forms at Hyderabad, Haridwar, Kashipur and Bidar. Aggregator and exchange descriptions characterise the company as engaged in APIs, contract development and manufacturing (CDMO), finished dosage formulations (FDF), specialty chemicals and retail branded formulations.
The company's own description
Vivimed's legacy self-description (2019 investor presentations) framed the group around three pillars — "Leveraging Global Presence," "Partnering Innovation," and "Delivering Affordable Chemistry" — and around two businesses: (i) a pharmaceuticals business anchored by UQUIFA (API and CDMO, with Spain, Mexico, Hungary and India operations, USFDA-approved sites) plus Indian FDF; and (ii) a specialty chemicals business (hair dyes, photochromic dyes, anti-microbials, imaging chemicals), which in 2019 the company itself labelled as "under divestment." A more recent company description (repeated by brokers) states that Vivimed manufactures APIs, intermediates and nutraceutical ingredients with an export orientation, and supports innovator pharma companies through custom synthesis from gram scale for clinical trials through launch and life-cycle management. That description appears to reflect the UQUIFA-era CDMO franchise and is likely outdated relative to the current asset base.
Independent characterisation
Our independent characterisation is that Vivimed is now a distressed, sub-scale Indian contract and own-brand formulations manufacturer whose revenue has fallen roughly 92% in five years (consolidated revenue from operations from ~INR 8,615 million in FY2021 to INR 699.9 million in FY2026). Its business model is predominantly product sales (manufactured formulations and APIs, including likely loan-licence and third-party manufacturing), with no meaningful subscription, licensing or service income disclosed. Its historic value-chain position spanned the middle of the pharma chain — API/intermediate synthesis and finished dosage manufacturing — selling to generic drug companies, innovators (CDMO) and distributors in India and export markets. Today, with working capital starved (inventory fell from INR 2,408 million in FY2022 to INR 127 million in FY2026), the plants are almost certainly operating far below installed capacity.
Revenue model mix
| Revenue type | Historic (to FY2021) | Current (FY2026) | Comment |
|---|---|---|---|
| Product sales — APIs / intermediates | Major (via UQUIFA) | Minor/unclear | UQUIFA no longer consolidated (see §3, §11) |
| Product sales — finished dosage forms | Meaningful | Dominant | Form G describes the business as dosage-form manufacturing |
| CDMO / custom synthesis services | Meaningful (UQUIFA, Soneas) | — | Likely negligible post-deconsolidation |
| Specialty chemicals | Dominant pre-2015; "under divestment" by 2019 | — | Residual activity, if any, undisclosed |
| Licensing / royalties | — | — | — |
| Other revenue | — | INR 63.19 million (FY2026) | S&P classification "other revenue" |
Customer types and end-markets
Customer types historically included global generic pharmaceutical companies (API buyers), innovator pharmaceutical companies (CDMO), personal-care and cosmetics majors (hair dyes, anti-microbials), ophthalmic lens makers (photochromic dyes), Indian pharma marketers (contract formulation), and government/export registrations (e.g., Uzbekistan product approvals in 2021). Current customer concentration is not disclosed.
Strategy
Stated strategy (historic)
Vivimed's last articulated strategy (2019 investor presentations) rested on three themes: leveraging global presence through UQUIFA and Soneas; partnering on innovation (CDMO for innovators, the Strides ANDA JV); and delivering affordable chemistry (cost-efficient API and formulation supply). The 2015 Clariant divestment statement explicitly set the direction: use proceeds to cut debt and refocus on pharmaceutical APIs and finished dosage forms in regulated markets. None of these strategies remains executable.
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Date | Initiative | Status |
|---|---|---|
| Jan 2025 onward | Compliance catch-up: delayed results filed; CFO appointed; revocation of trading suspension sought | Achieved — trading resumed 18 Dec 2025 |
| 2,025 | Debt restructuring/settlement proposals to SBI-led lenders (ongoing since 2021) | Failed — SBI assigned debt to Rare ARC (Oct 2025) |
| 10 Dec 2025 | Extraordinary General Meeting | Held via VC/OAVM |
| 12 Feb 2026 | Debtor-initiated Pre-packaged Insolvency Resolution Process (PPIRP) application under s.54A IBC | Overtaken by creditor-initiated CIRP (15 Apr 2026) |
| 14 Jun 2026 onward | IRP-run resolution process: Form G, PRA lists, information memorandum, resolution plans due 28 Aug 2026 | Ongoing |
No transformation programme, ESG commitment, cost programme with targets, or medium-term financial guidance has been published. Management guidance: none. In CIRP, the effective "strategy" is the CoC's selection of a resolution applicant (or, failing that, liquidation).
Products & Services
The company has not published a current product catalogue in any verifiable filing since its 2019 investor materials. The catalogue below distinguishes clearly between current (verified via 2026 insolvency documents) and legacy offerings.
Pharmaceuticals — current
| Product / offering | Description | Target customer | Status / year | Pricing |
|---|---|---|---|---|
| Finished dosage forms (tablets, capsules and other oral forms) | Manufactured at Hyderabad (2 units), Haridwar, Kashipur and Bidar | Indian pharma marketers, own brands, exports | Current (Form G, June 2026) | — |
| APIs and intermediates (India) | Bulk drug manufacturing (industry classification: "Pharmaceuticals – Indian – Bulk Drugs & Formulations") | Generic manufacturers | Current scale not disclosed | — |
| Retail branded formulations | Domestic branded generics | Indian trade channel | Referenced in aggregator descriptions | — |
| Export registrations — Uzbekistan | Approvals in 2021 for products including Bilastine tablets and an Orzole combination, from PIC/S- and Health Canada-approved site | CIS government/importers | 2021 approvals; current sales not disclosed | — |
| Favipiravir | Oral antiviral (COVID-19 era) approval received in 2021 | Domestic/export | 2021; likely discontinued commercially | — |
Installed capacity, quantity and value of main products sold in FY2026 were not legibly verifiable from the Form G copy retrieved; the IRP noted the FY2026 audit had not been finalised at Form G publication.
Pharmaceuticals — legacy (UQUIFA era)
| Offering | Description | Status |
|---|---|---|
| UQUIFA generic APIs | API portfolio including anti-ulcer and antidepressant compounds; USFDA-approved Spanish sites; ~80 years of operating history | No longer consolidated (from ~FY2022) |
| UQUIFA / Soneas CDMO | Custom synthesis from gram-scale through commercial supply for innovators; Hungarian development capabilities | Same as above |
| US ANDA portfolio (Strides JV) | 10 approved ANDAs; Alathur oral solids plant | Sold to Strides 2019 for INR 75 crore |
Specialty chemicals — legacy
| Product line | Description | Status |
|---|---|---|
| Hair dyes / hair colorants | Oxidative dye intermediates for hair-care majors | Portion sold to Clariant (2015); remainder status undisclosed |
| Photochromic dyes | Dyes for ophthalmic lenses; company claimed world leadership and patented processes | Labelled "under divestment" in 2019 |
| Anti-microbials | Preservatives/actives for personal and industrial care | Same |
| Imaging chemicals | Photographic/imaging intermediates | Same |
| Home and personal care ingredients (oral care, sun care, skin care) | Ingredients supplied to FMCG | Same |
Financial Narrative
All figures consolidated, INR millions, from S&P Global Market Intelligence via StockAnalysis.com (data updated after the FY2026 results filed 17 July 2026) unless noted. "Revenue" = total revenue including other revenue; "Revenue from operations" shown separately. Ratios marked are analyst calculations.
Income statement
FY2021 reference point: consolidated net sales INR 8,614.7 million and net loss INR 778.0 million (Capital Market/IIFL, FY2022 results coverage). The FY2026 consolidated net loss is reported by the company as INR 1,764.72 million.
Margins
Revenue from operations CAGR FY2022–FY2026: -26.3% per year (analyst calculation: (699.89/2373)^(1/4) − 1). FY2021–FY2026 CAGR (on INR 8,614.7M base): approximately -39% per year.
Commentary. The five-year income statement describes a business in continuous contraction with two step-downs. The first, in FY2022, was structural: revenue fell 72% as the UQUIFA group dropped out of the consolidation. The second, in FY2023, was a clean-up year: a negative gross profit (cost of revenue INR 2,746 million against revenue of INR 1,881 million) and an INR 892.8 million asset write-down point to large inventory write-offs — inventory fell from INR 2,408 million to INR 798 million in a single year. FY2024 and FY2025 showed apparent gross-margin "recovery" to ~49–55%, but this flattered by low revenue, absent interest accrual, and possibly by mix; operating losses persisted because the fixed-cost base (five plants, ~550 employees) could not be absorbed. FY2026 is the most severe operating year: gross margin collapsed to 3.4%, other operating expenses jumped to INR 1,237 million (from INR 388 million), and goodwill of INR 169 million disappeared from the balance sheet — consistent with large Q4 provisions and impairments taken ahead of or alongside the CIRP. Q3 FY2026 alone showed revenue of only INR 159.9 million and a loss of INR 165.5 million; the implied Q4 FY2026 loss (from aggregator EPS of approximately INR 17.74 per share for the quarter) is roughly INR 1.47 billion, which should be treated as an analyst inference pending review of the full results notes.
Balance sheet
Commentary. Net debt has been essentially flat at ~INR 3.5–4.0 billion for five years because no principal has been repaid and new borrowing has been negligible, but equity has been wiped out by cumulative losses of ~INR 6.5 billion (FY2022–FY2026). Net worth turned negative in FY2024 and reached INR −2.1 billion in FY2026 — before adjusting for ~INR 0.6 billion per year of unrecorded interest. The INR 1.49 billion of intangibles and INR 1.8 billion of long-term investments are of doubtful recoverable value in an insolvency context, implying tangible book value of approximately INR −3.6 billion (S&P). The default amount declared in the PPIRP filing — INR 5,125.3 million as of 31 January 2026 — is materially higher than the INR 3,748 million of borrowings in default cited in mid-2025, the difference presumably being accumulated interest and charges.
Cash flow
Commentary. Positive operating cash flow in FY2022, FY2023 and FY2026 was generated almost entirely by liquidating working capital (inventory and receivables), not by profitable operations — in FY2023, INR 1.61 billion came from inventory reduction, and in FY2026, INR 460 million from inventory and INR 288 million from receivables. This is the cash-flow signature of a business winding down its balance sheet. Capex has fallen to near zero (INR 9.5 million in FY2026 against D&A of INR 260 million), meaning the asset base is being consumed without reinvestment — a material concern for GMP compliance at regulated sites.
Ratios
Notes: ROE for FY2024–FY2026 is entered as 0 because equity was negative and the ratio is not meaningful. ROIC is not meaningful given negative EBIT and negative equity. All ratios are analyst calculations from S&P data.
Commentary. Every solvency metric is in distress territory. The current ratio of 0.37 in FY2026 and working capital of INR −2.8 billion confirm the company cannot meet current obligations. The apparent improvement in the cash conversion cycle to 36 days in FY2026 is not operational excellence; it reflects inventory being run down to INR 127 million and suppliers being stretched to ~264 payable days — a pattern consistent with the operational creditor petition (Blue Cube/Dow perchloroethylene supplies) that ultimately triggered the CIRP. Receivable days of ~236 suggest either weak collection or doubtful debts; Screener flagged high debtor days and contingent liabilities of INR 1.83 billion.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment (Historic Definition) Overview
| Segment (historic definition) | What it contained | Status today |
|---|---|---|
Pharmaceuticals | UQUIFA APIs and CDMO (Spain, Mexico, Hungary, India); Indian FDF plants; retail branded formulations; US ANDA JV (until 2019) | Indian FDF/API plants remain; UQUIFA not consolidated |
Specialty Chemicals | Hair dyes, photochromic dyes, anti-microbials, imaging chemicals; James Robinson (UK) | Identified lines sold to Clariant (2015); remainder "under divestment" (2019); current status not disclosed |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Consolidated revenue from operations (INR Mn) | 1,491 | 1,163 | 699.89 |
YoY growth (%) | -20.3 | -22.0 | -39.8 |
Operating income (INR Mn) | -418.07 | -288.5 | -1,722 |
Operating margin on total revenue (%) | -26.29 | -23.91 | -225.62 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Mn) | 2,373 | 1,871 | 1,491 | 1,163 | 699.89 |
Total revenue (INR Mn) | 2,386 | 1,881 | 1,590 | 1,206 | 763.08 |
Gross profit (INR Mn) | 828.14 | -864.86 | 867.76 | 590.21 | 25.61 |
Operating income / EBIT (INR Mn) | -250.73 | -2,051 | -418.07 | -288.5 | -1,722 |
EBITDA (INR Mn) | -67.91 | -1,859 | -218.66 | -86.26 | -1,461 |
Depreciation & amortisation (INR Mn) | 182.82 | 191.27 | 199.41 | 202.24 | 260.52 |
Interest expense, reported (INR Mn) | 385.42 | 350.04 | 12.13 | 17.35 | 41.7 |
Asset write-down (INR Mn) | 0 | 892.8 | 0 | 0 | 0 |
Pre-tax income (INR Mn) | -648.33 | -3,307 | -458.23 | -318.48 | -1,763 |
Net income (INR Mn) | -676.5 | -3,285 | -454.46 | -319.61 | -1,765 |
EPS basic (INR) | -8.16 | -39.62 | -5.48 | -3.85 | -21.15 |
EPS diluted (INR) | -8.16 | -39.62 | -5.48 | -3.85 | -21.15 |
Dividends per share (INR) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 34.72 | -45.99 | 54.56 | 48.92 | 3.36 |
Operating margin (%) | -10.51 | -109.03 | -26.29 | -23.91 | -225.62 |
EBITDA margin (%) | -2.85 | -98.86 | -13.75 | -7.15 | -191.48 |
Net margin (%) | -28.36 | -174.69 | -28.57 | -26.49 | -231.26 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Mn) | 12,660 | 9,951 | 9,509 | 9,208 | 7,535 |
Cash & equivalents (INR Mn) | 71.84 | 37.62 | 20.26 | 7.08 | 13.56 |
Accounts receivable (INR Mn) | 873.64 | 741.56 | 828.2 | 741.1 | 453.33 |
Inventory (INR Mn) | 2,408 | 797.6 | 640.62 | 587.55 | 127.15 |
Property, plant & equipment (INR Mn) | 4,026 | 2,988 | 2,835 | 2,715 | 2,548 |
Goodwill (INR Mn) | 169.14 | 169.14 | 169.14 | 169.14 | 0 |
Other intangibles (INR Mn) | 1,404 | 1,407 | 1,382 | 1,364 | 1,486 |
Goodwill & intangibles total (INR Mn) | 1,573.14 | 1,576.14 | 1,551.14 | 1,533.14 | 1,486 |
Long-term investments (INR Mn) | 1,988 | 1,988 | 1,685 | 1,685 | 1,805 |
Short-term debt incl. current LTD (INR Mn) | 2,979 | 3,163 | 3,134 | 3,127 | 3,258 |
Long-term debt (INR Mn) | 609.93 | 623.19 | 635.65 | 636.15 | 715.1 |
Total debt (INR Mn) | 3,589 | 3,810 | 3,788 | 3,763 | 3,973 |
Net debt (INR Mn) | 3,517 | 3,773 | 3,768 | 3,756 | 3,960 |
Other long-term liabilities (INR Mn) | 4,477 | 4,535 | 4,676 | 4,711 | 4,354 |
Total liabilities (INR Mn) | 9,017 | 9,556 | 9,564 | 9,560 | 9,640 |
Shareholders' equity (INR Mn) | 3,643 | 394.22 | -54.61 | -351.69 | -2,106 |
Working capital (INR Mn) | 1,339 | -851 | -677.42 | -806.44 | -2,801 |
Book value per share (INR) | 43.94 | 4.75 | -0.66 | -4.24 | -25.39 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Mn) | 275.4 | 353.22 | -239.91 | -17.51 | 77.03 |
Capital expenditure (INR Mn) | -164.1 | -49.68 | -20.39 | -45.31 | -9.47 |
Free cash flow (INR Mn) | 111.3 | 303.54 | -260.3 | -62.82 | 67.56 |
Cash interest paid (INR Mn) | 397.6 | 359.03 | 24.32 | 29.47 | 41.7 |
Net debt issued / (repaid) (INR Mn) | 293.82 | 21.21 | -36 | 79.11 | -19.36 |
Dividends paid (INR Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (INR Mn) | 0 | 0 | 0 | 0 | 0 |
Change in working capital (INR Mn) | 337.73 | 2,217 | -150.36 | 66.37 | 1,529 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%) — negative equity years not meaningful | -18.57 | -833.3 | 0 | 0 | 0 |
ROA, net income / year-end assets (%) | -5.34 | -33.01 | -4.78 | -3.47 | -23.42 |
Current ratio (x) | 1.36 | 0.8 | 0.83 | 0.8 | 0.37 |
Debt / equity (x) — negative = negative equity | 0.99 | 9.66 | -69.36 | -10.7 | -1.89 |
Net debt / EBITDA (x) — negative EBITDA, not meaningful | -51.79 | -2.03 | -17.23 | -43.54 | -2.71 |
Interest coverage, EBIT / reported interest (x) | -0.65 | -5.86 | -34.47 | -16.63 | -41.29 |
Asset turnover, revenue / assets (x) | 0.19 | 0.19 | 0.17 | 0.13 | 0.1 |
Receivable days (DSO, on revenue from ops) | 134.4 | 144.7 | 202.7 | 232.6 | 236.4 |
Inventory days (DIO, on cost of revenue) | 564.5 | 106 | 323.5 | 348 | 62.9 |
Payable days (DPO, on cost of revenue) | 98.2 | 73.4 | 222.6 | 233.5 | 263.5 |
Cash conversion cycle (days) | 600.7 | 177.3 | 303.6 | 347.1 | 35.8 |
Revenue by Region
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total consolidated revenue from operations (INR Mn) | 1,491 | 1,163 | 699.89 |
Share Price History
| Date | Price (INR) | Context | Source |
|---|---|---|---|
30 Sep 2015 | ~342–348 (face value INR 10, pre-split) | Clariant deal announcement | Business Standard |
28 Mar 2022 | 14.75 (52-week low 14.60) | SBI forensic audit | Business Standard |
19 Jan 2023 – 17 Dec 2025 | Suspended (limited trade-for-trade windows) | Reg. 34 non-compliance | NSE |
Dec 2025 – Jan 2026 | 52-week high 29.40 | Post-relisting speculative spike | Value Research |
8 Jun 2026 | 6.52 | Post-CIRP admission | Value Research |
26 Jul 2026 | 5.18 | — | Chola Securities |
52-week low (2026) | 5.15 | — | Value Research |
23 Sep 2026 | 5.30 | — | Multibagg |
7 Oct 2026 | 6.59 | Latest close | StockAnalysis |
Valuation Snapshot
| Multiple | Value | Comment |
|---|---|---|
Market capitalisation | INR 546.5M (INR 54.65 crore) | 82.93M shares × INR 6.59 |
Enterprise value | ~INR 4,506M | Mcap + FY2026 net debt INR 3,960M (excludes unrecorded interest and INR 4.35B other LT liabilities) |
EV/Sales | ~6.4x | On FY2026 revenue from operations INR 699.89M |
P/B | Not meaningful (negative book value INR −25.39/share consolidated) | Aggregators show −0.3x to −1.6x depending on standalone/consolidated basis |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | None — no sell-side coverage; MarketsMOJO quantitative rating "Strong Sell" |
Debt maturity profile | Effectively all debt in default and payable on demand; short-term debt INR 3,258M, long-term INR 715M (FY2026) |
Trading series | BE (trade-for-trade settlement) since 18 Dec 2025 |
Analyst Conclusions
Guidance and consensus
There is no management guidance (the board is suspended) and no consensus estimate. The relevant forward calendar is the CIRP timeline: resolution plans were due 28 August 2026; the CoC has met at least seven times (latest 10 September 2026); the statutory 180-day period from 15 April 2026 expires around 12 October 2026, extendable to a maximum of 330 days (including litigation time) — i.e., to approximately March 2027.
Bull case (grounded arguments)
-
Asset value exceeds equity price: PP&E of INR 2.55 billion across five licensed plants contrasts with a market capitalisation of ~INR 0.55 billion; a resolution plan that preserves even a sliver of equity could re-rate the stock.
-
MSME eligibility and ARC creditor: MSME status (Form G corrigendum) potentially widens the applicant pool, and Rare ARC — having bought SBI's exposure at a discount — may accept a pragmatic plan.
-
Legal overhang may lift: Telangana HC has already suspended the fraud classification and stayed CBI coercive steps; final relief would remove a key deterrent for bidders.
Bear case (grounded arguments)
-
Equity is structurally subordinated: claims (default of INR 5.1 billion as of January 2026, plus operational creditors and contingent liabilities of INR 1.8 billion) dwarf any plausible asset recovery; IBC plans routinely extinguish or massively dilute existing shares.
-
Operations are failing: FY2026 revenue fell 40% to INR 0.7 billion with EBITDA of INR −1.46 billion and gross margin of 3.4%, so the going-concern value is eroding during the process.
-
Liquidation risk is real: with near-zero capex, uncertain plant compliance and a criminal investigation overhang, bidder interest may be thin; failure to secure an approved plan leads to liquidation.
Catalysts and monitorables (next 12 months)
| Catalyst | Expected timing | Why it matters |
|---|---|---|
| Disclosure of resolution plans received / CoC vote | Q4 CY2026 | Determines equity treatment |
| CIRP extension application (beyond 180 days) | ~Oct 2026 | Signals process health |
| NCLT approval of any resolution plan | CY2027 | Change of control; possible capital reduction |
| Telangana HC final orders on CBI/SBI fraud matters | Ongoing | Bidder confidence; promoter eligibility |
| FY2026 AGM (extended by up to 3 months) | By ~Dec 2026 | Compliance continuity |
| Q1/Q2 FY2027 results under IRP | Q4 CY2026 | Run-rate erosion |
| Any liquidation application | Contingent | Worst case for equity |
Analyst verdict
Vivimed Labs is no longer an operating-company investment case; it is an insolvency case. Over roughly a decade the group went from a globally diversified specialty chemicals and API platform — with UK, Spanish, Mexican, Hungarian and US operations, a USFDA-approved API franchise and a US generics JV — to a sub-scale, India-only formulations manufacturer with five under-utilised plants, revenue from operations of INR 0.7 billion and an EBITDA loss of INR 1.46 billion in FY2026. The decline was not a single shock: leverage taken on to fund acquisitions was never adequately reduced despite the Clariant (2015) and Strides (2019) disposals; the COVID period pushed the SBI account into NPA status in 2021; the European API arm left the consolidation around FY2022; and governance failures — missed annual reports, a three-year trading suspension, qualified audits, and a CBI investigation — destroyed lender and investor trust.
Since 15 April 2026 the company has been under CIRP, run by an IRP and governed by its creditors. The defining question is not earnings power but recovery waterfall. On reported numbers, consolidated net worth is INR −2.1 billion before roughly INR 0.6 billion of unrecorded annual interest, while the declared default was INR 5.1 billion in January 2026. Against that, the hard-asset base (PP&E ~INR 2.5 billion) is unlikely to cover secured and operational claims in full, implying that existing equity will probably be extinguished or diluted to a nominal stake in any approved plan.
The share price (INR 6.59, market capitalisation ~INR 55 crore) therefore represents a speculative option on an unusually generous resolution outcome. For institutional purposes we classify the equity as uninvestable / avoid, with relevance limited to distressed-asset buyers evaluating the plants as a resolution applicant, and to creditors monitoring recovery. Key watchpoints are the CoC's plan selection, any CIRP extension, and final High Court orders on the fraud and CBI matters.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure | Background / notes |
|---|---|---|---|
Santosh Varalwar | Managing Director (promoter) | Director since 9 Nov 1989; MD re-appointed for 5 years w.e.f. 14 Aug 2020 (term to 13 Aug 2025; renewal proposed at AGM) | Founder-promoter; led the 2008–2018 acquisition strategy; also director of BBR Projects Pvt Ltd, UQUIFA India Pvt Ltd and others; named petitioner in Telangana HC proceedings vs CBI/SBI |
Dr. Manohar Rao Varalwar | Whole-Time Director (promoter) | WTD since 14 Aug 2015 (associated since inception) | Promoter-family elder |
Sandeep Varalwar | Whole-Time Director (promoter) | — | Promoter family |
Aparna Bidarkar | Director | Since 11 Dec 2024 | — |
Jarugula Siva Prasad | Director | Since 11 Dec 2024 | — |
Subbarathnamma Palepu | Director (independent, per MCA listing) | — | — |
Hari Gopal Jamalapuram | Independent Director | Died 18 Nov 2024 | — |
Umanath Varahabhotla | Independent Director (former) | — | Listed in older profiles |
Phaninder Nath P S | Chief Financial Officer | Appointed 10 Jan 2025; resigned citing health (early 2026) | Received CBI notice Jan 2026 |
Yugandhar Kopparthi | Company Secretary | Current | Received CBI notice Jan 2026 |
Mark Robbins | CEO, UQUIFA (historic) | Joined with UQUIFA acquisition 2011 | No longer relevant post-deconsolidation |
Major Shareholders
| Holder category | Stake (latest available) | Source / date |
|---|---|---|
Promoters & promoter group | ~7.6% (7.57%–7.77% across sources) | Share.market 28 Aug 2026; Chola; Screener |
Foreign institutional investors | ~1.6% | Share.market Aug 2026 |
Domestic institutional investors | ~0.2% | Share.market Aug 2026 |
Public / non-institutional | ~90.7% | Share.market Aug 2026 |
Competitive Landscape
Peer Comparison FY2026
| Dimension | Vivimed (FY2026) | Typical listed small/mid Indian pharma peer |
|---|---|---|
Revenue from operations | INR 699.89M | Generally INR several billion to tens of billions (an order of magnitude or more larger) |
Revenue growth | -39.8% YoY | Typically positive single to low double digits |
EBITDA margin | -191.5% | Typically positive, mid-teens to twenties |
R&D intensity | Not disclosed; likely negligible | Typically 1–8% of revenue |
Balance sheet | Negative equity; in CIRP | Solvent; most net-cash or moderately levered |
Recent Developments
--



